Higher urinary nitrate was associated with lower prevalence of congestive heart failure: results from NHANES

Zhuo Wu†, Ting Tian‡, Wang Ma*, Wen Gao* and Ninghong Song*

Abstract

Background: Some studies have reported that nitrate intake from vegetables was inversely associated with many vascular diseases, but few studies have paid attention to the relationship between urinary nitrate and cardiovascular diseases (CVDs). This cross-sectional study aimed to explore the connections between urinary nitrate and prevalence of CVDs.

Methods: The data of this study was collected from National Health and Nutrition Examination Survey (NHANES). Finally, several years' data of NHANES were merged into 14,894 observations. Logistic regression models were used to examine the associations between urinary nitrate and CVDs by using the 'survey' package in R software (version 3.2.3).

Results: In the univariable logistic analysis, significant association was discovered between urinary nitrate and congestive heart failure, coronary heart disease, angina pectoris, myocardial infarction (all $P < 0.001$). By adjusting related covariates, the multivariable logistic analysis showed that the significant association only existed between urinary nitrate and congestive heart failure ($\text{OR} = 0.651, 95\% \text{CI } 0.507–0.838, P < 0.001$). Compared to Q1 urinary nitrate level as reference, the risk for prevalent heart failure diminished along with increasing levels of urinary nitrites, ($\text{OR of Q2 level} = 0.633, 95\% \text{CI } 0.403–0.994$), ($\text{OR of Q3 level} = 0.425, 95\% \text{CI } 0.230–0.783$), ($\text{OR of Q4 level} = 0.375, 95\% \text{CI } 0.210–0.661$), respectively. Moreover, urinary nitrate levels were associated with congestive heart failure in a dose-dependent manner in both 20–60 years group, 60+ years group and male, female group ($P < 0.001$, $P = 0.011$ and $P = 0.009$, $P = 0.004$).

Conclusions: Independent of related covariates, higher urinary nitrate was associated with lower prevalent congestive heart failure.

Keywords: Urinary nitrate, Cardiovascular diseases, Congestive heart failure, Logistic regression model, Complex sample, NHANES

Background

In the past, nitrate was considered to be associated with detrimental health outcomes such as cancer [1, 2], however, understanding of the health impact of nitrate has recently undergone radical changes. In recent years, many researchers implemented studies on the relationship between dietary nitrate and vascular health [1–4]. It has been found that a short-term increase in nitrate intake can lower blood pressure [2] and improve endothelial function [4]. The circulation nitrate in...
human body mainly originate from two ways: oxidation of endogenously produced nitric oxide (NO) and our diet [5]. Dietary nitrate, abundant in beetroot and green leafy vegetables, is a potential and important alternative source for the production of NO via the nitrate–nitrite–NO pathway [6]. Nitrate from diet is rapidly absorbed in the small intestine and approximately 75% will ultimately be excreted in the urine [7, 8]. Thus, urinary nitrate can better reflect the level of nitrate in human body.

Cardiovascular diseases (CVDs) is the leading cause of death for entire population around the world [9]. Many studies have reported and demonstrated that increased dietary nitrate intake can decrease the risk of vascular diseases [10–13]. As is well known that endothelial dysfunction, especially impaired endothelium-dependent vasodilation mediated by NO, is a crucial early event in the development of CVDs [14]. However, up to now, few studies figured out the relationship between urinary nitrate and CVDs. Therefore, we tried to explore in the study.

Methods

Data source and study population

The National Health and Nutrition Examination Survey (NHANES) is an ongoing cross-sectional monitoring survey of the non-institutionalized US civilians, which were managed by the US National Center for Health Statistics (Centers for Disease Control and Prevention, Atlanta, GA, USA) [15]. It was conducted by complex survey design including oversampling, survey non-response, and post-stratification, thus selecting a representative US sample. The survey examines a nationally representative sample of about 5000 persons each year. These persons are located in counties across the country, 15 of which are visited each year. Sample weights were set uniquely for each participant for accounting the complex survey design in NHANES. Physical examinations, clinical laboratory examinations, and related measurement procedures were collected by Mobile Examination Center. This cross-sectional study data was collected from 5 surveys (2001–2002, 2005–2006, 2007–2008, 2009–2010 and 2011–2012). Besides, participants with missing information of CVDs and urinary nitrate were excluded in this study. Then demography, hypercholesterolemia, diabetes, hypertension, BMI and cotinine information of each subject were extracted. All the data were finally merged into totally 14,894 observations. Details were shown on Fig. 1.

Urinary nitrate measurement

Nitrate were measured in all available urine samples from 1/3 subsets of study participants aged over 6 years old in NHANES 2001–2002, 2009–2010 and 2011–2012. In 2005–2006 and 2007–2008 NHANES, nitrate was tested in participants aged over 6 years old. Urine specimens for urinary nitrate testing were processed, stored, and transferred to the Division of Environmental Health Laboratory Sciences, National Center for Environmental Health, and Centers for Disease Control and Prevention. All details for the urine specimen collection and processing were elucidated in the NHANES LPM (NHANES Laboratory/Medical Technologists Procedures Manual). All samples were stored at −20 °C before being transported to National Center for Environmental Health for testing. Samples were analyzed for nitrate by using ion chromatography tandem mass spectrometry [16]. The NHANES kept to the quality assurance and quality control (QA/QC) protocols which met the 1988 Clinical Laboratory Improvement Act mandates. Details can been in the NHANES LPM.

Cardiovascular diseases

In NHANES, the CVDs were provided by a self-reported personal interview. Among the tested participants who needed to answer the CVDs conditions were all over 20 years old. Participants would be considered to have CVDs including congestive heart failure, coronary heart disease, angina and myocardial infarction if they confirmed yes to the questions “Has a doctor or other health professional ever told you that you had congestive heart failure?”, “Has a doctor or other health professional ever told you that you had coronary heart disease?”, “Has a doctor or other health professional ever told you that you had angina, also called angina pectoris?”, “Has a doctor or other health professional ever told you that you had a heart attack (also called myocardial infarction)”? respectively. These questions were included in the medical conditions part of the interview survey, and the diseases condition of participants were based on the medical history diagnosed by the clinicians or medical institutions. Besides, the explanations in the manuals described these diseases condition and differences which can make it easier for the interviewer and participants to understand, and we displayed them as followings.

Congestive heart failure Is when the heart can’t pump enough blood to the body. Blood and fluid “back up” into the lungs, which makes you short of breath. Heart failure causes fluid buildup in and swelling of the feet, legs and ankles.

Interviewer Do not count heart murmurs, irregular heart beats, chest pain or heart attacks.

Coronary heart disease Is when the blood vessels that bring blood to the heart muscle become narrow and hardened due to plaque (plak). Plaque buildup is called
Atherosclerosis (ATH-er-o-skler-O-sis). Blocked blood vessels to the heart can cause chest pain or a heart attack.

**Interviewer** If the respondent reports chest pain, probe if a doctor told them that they had blocked blood vessels or coronary heart disease.

**Angina (Angina Pectoris)** (AN-ji-na or an-JI-na). Angina is chest pain or discomfort that occurs when the heart does not get enough blood.

**Heart attack (Myocardial Infarction)** A heart attack happens when there is narrowing of a blood vessel that supplies the heart. A blood clot can form and suddenly cut off the blood supply to the heart muscle. This damage causes crushing chest pain that may also be felt in the arms or neck. There can also be nausea, sweating, or shortness of breath.
Covariates
A wide range of socio-demographic variables and medical histories were collected in NHANES including sex, age (years), ethnicity (Mexican American, Other Hispanic, Non-Hispanic White, Non-Hispanic Black and Other Race—Including Multi-Racial), BMI (Individuals were divided as overweight if their BMI value ranging from 25 to 30 kg/m², and obese if their BMI ≥ 30 kg/m² on the basis of the World Health Organization (WHO) standards), serum cotinine (non-smoker defined as serum cotinine ≤ 10 ng/mL and smoker defined as serum cotinine > 10 ng/mL) [17], poverty income ratio (PIR) [poverty: PIR ≤ 1, beyond the poverty threshold: PIR > 1], hypertension, hypercholesterolemia and diabetes history. The history of hypertension, hypercholesterolemia and diabetes were defined as participants confirmed yes to the questions “Have you ever been told by a doctor or other health professional that you had hypertension, also called high blood pressure?”, “Have you ever been told by a doctor or other health professional that your blood cholesterol level was high?” and “Have you ever been told by a doctor or health professional that you have diabetes or sugar diabetes?”.

Statistical analyses
All statistical analysis was on the R software (version 3.2.3). Logistic regression models with were used to examine the associations between urinary nitrate and CVDs by using the “survey” package. Each analysis used sample weights to estimate representatives of the US population. Logistic regression models with complex sample were applied to test the associations between CVDs and urinary nitrate adjusted by covariates (age, sex, ethnicity, serum cotinine, BMI, PIR, hypertension, hypercholesterolemia and diabetes history). We would perform logistic analysis twice, taking urinary nitrate as continuous variables and categorical factors respectively. In the model which used continuous urinary nitrate, urinary nitrate was normalized for creatinine as follows: urinary nitrate concentration (ng/mL)/(urinary creatinine (mg/dL)/100) = μg nitrate/g creatinine. Then normalized nitrate was transferred by the natural log transformation for the significant deviation from the normal distribution. In the model using categorical urinary nitrate, the level of urinary nitrates was divided into quartiles (Q1: ≤ 26,100; Q2: 26,100–45,000; Q3: 45,000–70,600; Q4: > 70,600) by the interquartile. Both models were applied for the stratified analysis by genders and age groups (younger people age 20–60 years and older people age over 65 years) between CVDs and nitrate. All significance tests were two-sided with significant threshold of 0.05.

Results
General demographic information
14,894 participants were included in this study from 5 NHANES surveys. Demographic characteristics of all participants and different urinary nitrate groups were shown in Table 1. Genders had a balance of distribution which female accounted for 51.36%. The prevalence of hypertension, hypercholesterolemia and diabetes were 32.86% (4883), 41.21% (4415) and 11.10% (1626) respectively. Participants with any of the congestive heart failure, coronary heart disease, angina and myocardial infarction had lower urinary nitrate levels, demonstrated in Additional file 1: Table S1.

Association between urinary nitrate and CVDs
To explore whether urinary nitrate levels were associated with any CVDs, logistic regression methods were used by conducting univariable and multivariable analyses. Pronounced association were found between urinary nitrate levels and prevalent congestive heart failure, coronary heart disease, angina pectoris and myocardial infarction in the univariable logistic analysis (all \( P < 0.001 \)) (Tables 2, 3). After adjusting related covariates, the multivariable logistic analysis showed that the significant association only existed between urinary nitrate and occurrence of congestive heart failure (\( \text{OR} = 0.651, 95\% \text{ CI} 0.507–0.838, P < 0.001 \)), details were displayed in Table 2. Furthermore, the concentration of urinary nitrate was divided into quartiles (Q1, Q2, Q3 and Q4) according to the interquartile. Compared to Q1 which was reference group, the Q2, Q3 and Q4 had pronounced negative correlation with congestive heart failure (\( \text{OR} = 0.633, 95\% \text{ CI} 0.403, 0.994 \)), (\( \text{OR} = 0.425, 95\% \text{ CI} 0.230, 0.783 \)), (\( \text{OR} = 0.375, 95\% \text{ CI} 0.210, 0.661 \)), respectively. Trend test showed statistical significance (\( P < 0.001 \)) in Table 3.

Stratification analysis
In view of the different distribution of congestive heart failure in various age and gender groups, further stratification logistic analyses were performed. Corresponding results were listed in Table 4. In the 20–60 years group, urinary nitrate levels were associated with congestive heart failure in a dose-dependent manner (\( P < 0.001 \)). Compared with Q1 reference group, risk of having congestive heart failure in the Q3 group (\( \text{OR} = 0.224, 95\% \text{ CI} 0.082, 0.608 \)) and Q4 group (\( \text{OR} = 0.195, 95\% \text{ CI} 0.071, 0.534 \)) were significantly lower. It was found that urinary nitrate levels had significantly negative correlation with congestive heart failure in >60 years group (\( P = 0.011 \)). Q4 group had lower congestive heart failure than Q1 group (\( \text{OR} = 0.485, 95\% \text{ CI} 0.251, 0.936 \)). In addition, regardless of genders, the inverse relationship between
Table 1  Baseline characteristics of all study participants divided by urinary nitrate groups

| Variables               | All participants, n = 14,894 | Urinary nitrate (ng/mL) | P     |
|-------------------------|-------------------------------|-------------------------|-------|
|                         |                               | Q1, n = 3714            | Q2, n = 3736 | Q3, n = 3708 | Q4, n = 3736 |       |
| Age                     | 48.67 (18.00)                 | 53.29 (18.48)           | 50.09 (18.10) | 47.11 (17.66) | 44.22 (16.44) | < 0.001|
| Gender                  |                               |                         |              |              |              |       |
| Male (N, %)             | 7245 (48.64)                  | 1415 (38.10)            | 1761 (47.14) | 2002 (53.99) | 2067 (55.33) |       |
| Female (N, %)           | 7649 (51.36)                  | 2299 (61.90)            | 1975 (52.86) | 1706 (46.01) | 1669 (44.67) |       |
| Race (N, %)             |                               |                         |              |              |              | < 0.001|
| Mexican American        | 2668 (17.91)                  | 614 (16.53)             | 614 (18.09)  | 686 (18.50)  | 692 (18.52)  |       |
| Other Hispanic          | 1175 (7.89)                   | 286 (7.70)              | 293 (7.84)   | 306 (8.25)   | 290 (7.76)   |       |
| Non-Hispanic White      | 7011 (47.07)                  | 1916 (51.59)            | 1740 (46.57) | 1653 (44.58) | 1702 (45.56) |       |
| Non-Hispanic Black      | 3184 (21.38)                  | 710 (19.22)             | 846 (22.64)  | 862 (23.25)  | 766 (20.50)  |       |
| Other race—including multi-racial | 856 (5.75) | 188 (5.06)             | 181 (4.84)   | 201 (5.42)   | 286 (7.66)   |       |
| PIR (N, %)              |                               |                         |              |              |              | 0.276  |
| ≤ 1                     | 2719 (19.74)                  | 660 (19.32)             | 657 (19.02)  | 671 (19.51)  | 731 (21.12)  |       |
| > 1                     | 11,052 (80.26)                | 2757 (80.68)            | 2797 (80.98) | 2786 (80.49) | 2730 (78.88) |       |
| Cotinine (N, %)         |                               |                         |              |              |              | < 0.001|
| ≤ 0.01                  | 10,547 (74.44)                | 2900 (82.18)            | 2749 (77.22) | 2585 (73.31) | 2313 (65.10) |       |
| > 0.1                   | 3621 (25.56)                  | 629 (17.82)             | 811 (22.78)  | 941 (26.69)  | 1240 (34.90) |       |
| BMI (N, %)              |                               |                         |              |              |              | < 0.001|
| < 25                    | 4448 (30.33)                  | 1231 (33.91)            | 1118 (30.31) | 979 (26.81)  | 1120 (30.33) |       |
| 25–30                   | 5019 (34.23)                  | 1228 (33.83)            | 1268 (34.37) | 1289 (35.30) | 1234 (33.41) |       |
| > 30                    | 5197 (35.44)                  | 1171 (32.62)            | 1303 (35.32) | 1384 (37.90) | 1339 (36.26) |       |
| Hypertension (N, %)     |                               |                         |              |              |              | < 0.001|
| No                      | 9977 (67.14)                  | 2208 (59.53)            | 2397 (64.31) | 2595 (70.23) | 2777 (74.47) |       |
| Yes                     | 4883 (32.86)                  | 1501 (40.47)            | 1330 (35.69) | 1100 (29.77) | 952 (25.53)  |       |
| Hypercholesterolemia (N, %) | 6298 (58.79) | 1618 (56.75) | 1579 (56.92) | 1569 (60.30) | 1532 (61.63) |       |
| No                      | 4415 (41.21)                  | 1233 (43.25)            | 1195 (43.08) | 1033 (39.70) | 954 (38.37)  | < 0.001|
| Yes                     | 13,017 (88.90)                | 3118 (85.31)            | 3229 (87.91) | 3265 (89.80) | 3405 (92.55) | < 0.001|
| Diabetes (N, %)         |                               |                         |              |              |              |       |
| No                      | 1626 (11.10)                  | 537 (14.69)             | 444 (12.09)  | 371 (10.20)  | 274 (7.45)   |       |
| Yes                     |                               |                         |              |              |              |       |

PIR poverty impact ratio, BMI body mass index, Cotinine the predominate metabolite of nicotine

* Urine nitrate was divided to four levels by quartile (Q1: ≤ 26,100; Q2: 26,100–45,000; Q3: 45,000–70,600; Q4: > 70,600)

Table 2 Logistic regression results for relationship between urinary nitrate (log transformation) and various cardiovascular diseases

|                     | OR (95%CI) | P     | OR (95%CI) | P     |
|---------------------|------------|-------|------------|-------|
| Congestive heart failure | 0.980 (0.976, 0.984) | < 0.001 | 0.651 (0.507, 0.838) | < 0.001 |
| Coronary heart disease | 0.989 (0.985, 0.993) | < 0.001 | 1.052 (0.776, 1.426) | 0.745  |
| Angina pectoris       | 0.992 (0.988, 0.996) | < 0.001 | 0.894 (0.720, 1.110) | 0.309  |
| Myocardial infarction | 0.990 (0.985, 0.994) | < 0.001 | 1.076 (0.869, 1.331) | 0.503  |

* Model was not adjusted by any covariate

b Model was adjusted by age, gender, race/ethnicity, poverty income ratio, cotinine, BMI, hypertension, hypercholesterolemia and diabetes (poverty income ratio: Q1: ≤ 1, Q2: > 1; cotinine: Q1: ≤ 0.01, Q2: 0.01–10, Q3: > 10; BMI: Q1: < 25; Q2: 25–30; Q3: > 30)
urinary nitrate and congestive heart failure still existed in both male and female groups ($P = 0.009$, $P = 0.004$, respectively). There were no connections between urinary nitrate and coronary heart disease, angina in each gender and age groups. Furthermore, we performed age stratification in each sex group, as we can see from Table 5, the significant association existed in every subgroup except in >60 years female subgroup.

**Discussion**

Higher urinary nitrate was associated with lower prevalence of congestive heart failure from this cross-sectional study. Subjects with congestive heart failure had significant lower urinary nitrate levels. Nitrate and nitrite, previously known as unnecessary residues in the food chain, have potentially carcinogenic effects, especially positively related to gastric cancer [18]. Nowadays, it is widely recognized that nitrite and nitrate are important reservoirs of NO and crucial for maintenance of NO physiological levels [5]. Dietary nitrate can affect NO in the circulation in a dose-dependent manner by increasing the levels of nitrite, NO, and related nitroso compounds [19–22]. Through the classic L-arginine-NO-synthase pathway, inert nitrogen anion circulates in vivo to form NO [23].

After adjusting the involved covariates, the negative correlation between CVDs and urinary nitrate only existed in patients with congestive heart failure. Worldwide, heart failure is a major public health problem with a total number more than 23 million and still rising [24]. Heart failure is the terminal conditions of many heart diseases, for instance, ischemic heart disease, coronary artery disease and atrial fibrillation. This disease has tremendous undesirable consequences which can lower the quality of life and even lead to death [25]. Numerous human intervention studies have investigated the effects of dietary nitrate on vascular health [3, 13, 26, 27]. These studies have shown that increased nitrate intake can improve vasorelaxation [27], lower blood pressure [2] and improve function of endothelium [4], which

**Table 3 Logistic regression results for relationship between urinary nitrate levels and various cardiovascular diseases**

|                      | OR (95% CI) | $P$ for trend | OR (95% CI) | $P$ for trend |
|----------------------|------------|---------------|------------|---------------|
| Congestive heart failure |            |               |            |               |
| Q1 Ref               |            | $< 0.001$     | Ref        | $< 0.001$     |
| Q2 0.978 (0.971, 0.986) |            | 0.633 (0.403, 0.994) |           |               |
| Q3 0.970 (0.964, 0.977) |            | 0.425 (0.230, 0.783) |           |               |
| Q4 0.967 (0.960, 0.973) |            | 0.375 (0.210, 0.661) |           |               |
| Coronary heart disease |            |               |            |               |
| Q1 Ref               |            | $< 0.001$     | Ref        | 0.567         |
| Q2 1.000 (0.992, 1.008) |            | 0.981 (0.618, 1.555) |           |               |
| Q3 0.986 (0.978, 0.993) |            | 0.632 (0.365, 1.094) |           |               |
| Q4 0.983 (0.975, 0.991) |            | 1.003 (0.586, 1.717) |           |               |
| Angina pectoris      |            |               |            |               |
| Q1 Ref               |            | $< 0.001$     | Ref        | 0.745         |
| Q2 0.994 (0.988, 1.001) |            | 0.800 (0.446, 1.437) |           |               |
| Q3 0.990 (0.984, 0.996) |            | 0.462 (0.252, 0.846) |           |               |
| Q4 0.989 (0.982, 0.995) |            | 0.697 (0.372, 1.303) |           |               |
| Myocardial infarction |            |               |            |               |
| Q1 Ref               |            | $< 0.001$     | Ref        | 0.617         |
| Q2 0.992 (0.984, 0.983) |            | 0.785 (0.499, 1.233) |           |               |
| Q3 0.984 (0.976, 0.992) |            | 0.751 (0.437, 1.288) |           |               |
| Q4 0.983 (0.975, 0.991) |            | 0.913 (0.535, 1.558) |           |               |

* Model was not adjusted by any covariate

* Model was adjusted by age, gender, race/ethnicity, poverty income ratio, cotinine, BMI, hypertension, hypercholesterolemia and diabetes. (poverty income ratio: Q1: $\leq 1$, Q2: $> 1$; cotinine: Q1: $\leq 0.01$, Q2: $0.01–10$, Q3: $> 10$; BMI: Q1: $< 25$; Q2: $25–30$; Q3: $> 30$)

**Table 4 Logistic regression results for relationship between urinary nitrate levels and congestive heart failure stratified by age groups and genders respectively**

| Urinary nitrate | 20–60 year OR (95%CI) | 60+ year OR (95%CI) | Male OR (95%CI) | Female OR (95%CI) |
|----------------|------------------------|---------------------|----------------|-------------------|
| Q1 Ref         |                        | Ref                 | Ref            | Ref               |
| Q2             | 0.621 (0.287, 1.343)   | 0.621 (0.359, 1.077) | 0.629 (0.343, 1.152) | 0.690 (0.354, 1.344) |
| Q3             | 0.224 (0.082, 0.608)   | 0.508 (0.255, 1.011) | 0.356 (0.138, 0.915) | 0.600 (0.290, 1.242) |
| Q4             | 0.195 (0.071, 0.534)   | 0.485 (0.251, 0.936) | 0.441 (0.217, 0.899) | 0.201 (0.076, 0.530) |
| $P$ for trend  | $< 0.001$              | 0.011               | 0.009          | 0.004             |

All models were adjusted by age, gender, race/ethnicity, poverty income ratio, cotinine, BMI, hypertension, hypercholesterolemia and diabetes (poverty income ratio: Q1: $\leq 1$, Q2: $> 1$; cotinine: Q1: $\leq 0.01$, Q2: $0.01–10$, Q3: $> 10$; BMI: Q1: $< 25$; Q2: $25–30$; Q3: $> 30$)

* Urinary nitrate was divided to four levels by quartile (Q1: $\leq 26,100$; Q2: $26,100–45,000$; Q3: $45,000–70,600$; Q4: $> 70,600$)
eventually resulted in lower death risk of atherosclerotic vascular disease (ASVD) [10]. NO is an endothelium-derived relaxing factor (EDRF) endogenously biosynthesized from L-arginine, oxygen, and Nicotinamide Adenine Dinucleotide Phosphate (NADPH) via various nitric oxide synthase (NOS) enzymes [28]. The vascular endothelium (inner lining) uses NO to give a signal of making surrounding smooth muscle relaxing, thus resulting in the process of vasodilation and increasing blood flow [29, 30]. In an intervention study, patients with systolic heart failure were well-tolerated for acute dietary NO3− intake, and had enhanced NO bioavailability and exercise capacity [31]. In addition, NO3− increased vasodilatory ability, cardiac output reserves and reduced arterial wave reflections in heart failure patients with Preserved Ejection Fraction [32].

About 65–70% of nitrate is excreted in urine in the 24 h and less than 1% is excreted into feces [33]. Urinary nitrate levels are generally considered as appropriate biomarkers for assessing chronic exposure. Nitrate in blood is also a good marker of human exposure; however, it is more susceptible to recent exposures. Therefore, urinary nitrate can represent stable and real nitrate concentration in human body [34–36]. At present, there are lots of researches at home and abroad focusing on the relationship between urinary nitrate and other diseases. For example, the decrease in urinary nitrate concentration in neonates with persistent pulmonary hypertension (PPHN) implied a role of NO in the pathogenesis of PPHN [37]. Furthermore, from the 2005–2006 National Health and Nutrition Examination Survey, Ko et al. [38] found the inverse association between urinary nitrate and thiocyanate concentrations in U.S. Adults.

Our data suggested that the remarkable relationships was existed in different gender and age groups. From self-reported data obtained from 2003 to 2006 National Health and Nutrition Examination Survey, the prevalence of heart failure increased with age, and males were higher than females. There are differences in gene expression and physiology between men and women, so that gender has a broad impact on human biology and disease development [39]. Studies have indicated that estrogen plays a protective role in the maintenance of cardiovascular health among females, reducing the occurrence of CVDs, thereby reducing the CVDs mortality rate in women. In our study, the association between urinary nitrate levels and congestive heart failure was no longer meaningful in > 60 year female subgroup. This could be explained by that the decrease of estrogen secretion in postmenopausal women [40].

Other studies had evaluated the relationship between nitrate and atherosclerotic vascular disease (ASVD), carotid atherosclerosis and ischemic cerebrovascular disease [10]. However, it is worth mentioning that our study comprehensively and systematically explored the association of urinary nitrate with various kinds of CVDs based on large samples from well-designed database. There are still some limitations in this study. For instance, exposure misclassification would exist because of imperfect single measurements of urinary nitrate as markers of chronic exposure. In addition, the cross-sectional study might hinder the real interpretation of causality from the results. The longitudinal study design is in necessity to understand the true association between nitrate and congestive heart failure. Besides, the definitions of these CVDs are based on the self-reported information in the face-to-face interview, there may be some bias which affected the results to some extent. However, previous scholars also do researches on the CVDs and other diseases based on the self-reported information from the NAHENS [41, 42]. The study design of NAHENS is reasonable, and investigators have received good training. When conducting the interview, a computer-aided investigation system can help participants easily understanding health-related questions. For the cardiovascular

### Table 5 Logistic regression results for relationship between urinary nitrate levels and congestive heart failure stratified by age groups and genders

| Urinary nitratea | Male | Female |
|-----------------|------|--------|
|                  | 20–60 | 60+    | 20–60 | 60+    |
| Q1               | Ref   | Ref    | Ref   | Ref    |
| Q2               | 0.829 (0.317, 2.166) | 0.531 (0.249, 1.135) | 0.344 (0.099, 1.186) | 0.807 (0.376, 1.703) |
| Q3               | 0.138 (0.033, 0.582) | 0.407 (0.160, 1.033) | 0.507 (0.118, 2.171) | 0.672 (0.287, 1.573) |
| Q4               | 0.262 (0.074, 0.925) | 0.494 (0.214, 1.140) | 0.058 (0.006, 0.519) | 0.291 (0.099, 0.858) |
| P for trend      | 0.008 | 0.049  | 0.024 | 0.053  |

All models were adjusted by age, gender, race/ethnicity, poverty income ratio, cotinine, BMI, hypertension, hypercholesterolemia and diabetes (poverty income ratio: Q1: ≤ 1, Q2: > 1; cotinine: Q1: ≤ 0.01, Q2: 0.01–10, Q3: > 10; BMI: Q1: < 25; Q2: 25–30; Q3: ≥ 30).

* Urinary nitrate was divided to four levels by quartile (Q1: ≤ 26,100; Q2: 26,100–45,000; Q3: 45,000–70,600; Q4: > 70,600)
disease outcomes in this study, there are detailed problem description and explanation for each question. Based on the conclusion of medical diagnosis recall, the results are relatively reliable.

**Conclusions**

Higher urinary nitrate was associated with lower prevalence of congestive heart failure and these significant results were still existed in most gender and age groups. This can remind us that raised intake of dietary nitrate may help resist the occurrence of congestive heart failure in particular populations.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s12872-020-01790-w.

---

**References**

1. Mensinga TT, Speijers GJ, Meulenbelt J. Health implications of exposure to environmental nitrogenous compounds. Toxicol Rev. 2003;22(1):41–51.

2. Siervo M, Lara J, Ogbonnwan I, Mathers JC. Inorganic nitrate and beetroot juice supplementation reduces blood pressure in adults: a systematic review and meta-analysis. J Nutr. 2013;143(6):818–26.

3. Bondonno CP, Croft KD, Ward N, Considine MJ, Hodgson JM. Dietary flavonoids and nitrate effects on nitric oxide and vascular function. Nutr Rev. 2015;73(4):216–35.

4. Lara J, Ashor AW, Oggoni C, Akuwula A, Mathers JC, Siervo M. Effects of inorganic nitrate and beetroot supplementation on endothelial function: a systematic review and meta-analysis. Eur J Nutr. 2016;55(2):451–9.

5. Rajapakse NW, Nanayakkara S, Kaye DM. Pathogenesis and treatment of the cardiorenal syndrome: implications of L-arginine-nitric oxide pathway impairment. Pharmacol Ther. 2015;154:1–12.

6. Weitzberg E, Lundberg JO. Novel aspects of dietary nitrate and human health. Annu Rev Nutr. 2013;33:129–59.

7. McKnight GM, Smith LM, Drummond RS, Duncan CW, Golden M, Benjamin N. Chemical synthesis of nitric oxide in the stomach from dietary nitrate in humans. Gut. 1997;40(2):211–4.

8. Lundberg JO, Weitzberg E, Lundberg JM, Alving K. Intragastric nitric oxide production in humans: measurements in expelled air. Gut. 1994;35(11):1543–6.

9. WHO: World Heart Day 2017, vol 2019, 2019.

10. Blekenhorst LC, Bondonno CP, Lewis JR, Devine A, Woodman RJ, Croft KD, Lim WH, Wong G, Beilin LJ, Prince RL, et al. Association of dietary nitrate with atherosclerotic vascular disease mortality: a prospective cohort study of older adult women. Am J Clin Nutr. 2017;106(1):207–16.

11. Bondonno CP, Blekenhorst LC, Prince RL, Ivey KL, Lewis JR, Devine A, Woodman RJ, Lundberg JO, Croft KD, Thompson PL, et al. Association of vegetable nitrate intake with carotid atherosclerosis and ischemic cerebrovascular disease in older women. Stroke. 2017;48(7):1724–9.

12. Larsen FJ, Ekblom B, Sahlin K, Lundberg JO, Weitzberg E. Effects of dietary nitrate on blood pressure in healthy volunteers. N Engl J Med. 2006;355(26):2792–3.

13. Webb AJ, Patel N, Loukogeorgakis S, Okorie M, Aboud Z, Misra S, Rashid R, Miall P, Deanfield J, Benjamin N, et al. Acute blood pressure lowering, vasoprotective, and antplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension. 2008;51(3):784–90.

14. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekstein VE, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990;81(2):491–7.

15. Johnson CL, Paulose-Ram R, Ogden CL, Carroll MD, Kruszon-Moran D, Dohrnmann SM, Curtin LR. National Health and Nutrition Examination Survey: analytic guidelines, 1999–2010. In: Vital and health statistics. Series 2, Data evaluation and methods research, 2013(161). p. 1–24.

16. Valentin-Blasini L, Mauldin JP, Maple D, Blount BC. Analysis of perchlorate, thiocyanate, and nitrate among females aged 15–44 years: data from National Health and Nutrition Examination Survey. 2003–2008. Chemosphere. 2013;91(7):882–7.

17. Jain RB. Impact of pregnancy and other factors on the levels of urinary perchlorate, thiocyanate, and nitrate among females aged 15–44 years: data from National Health and Nutrition Examination Survey. 2003–2008. Chemosphere. 2013;91(7):882–7.

18. Joossens JV, Hill MJ, Elliott P, Stahlmier R, Lesaffre E, Dyer A, Nichols R, Kesteloot H. Dietary salt, nitrate and stomach cancer mortality in 24 countries. European Cancer Prevention (ECP) and the INTERSALT Cooperative Research Group. Int J Epidemiol. 1996;25(3):494–504.
19. Lundberg, JO, Govoni, M. Inorganic nitrate is a possible source for systemic generation of nitric oxide. Free Radical Biol Med. 2004;37(3):395–400.
20. Govoni, M, Jansson, EA, Weitzberg, E, Lundberg, JO. The increase in plasma nitrite after a dietary nitrate load is markedly attenuated by an antibacterial mouthwash. Nitric Oxide Biol Chem. 2008;19(4):333–7.
21. Petersson, J, Carlström, MM, Schreiber, O, Phillipson, M, Christoffersson, G, Roos, S, Jansson, EA, Persson, AE, Lundberg, JO, et al. Gastroprotective and blood pressure lowering effects of dietary nitrite are abolished by an antiseptic mouthwash. Free Radic Biol Med. 2009;46(8):1068–75.
22. Bondonno, CP, Croft, KD, Puddey, IB, Considine, MJ, Yang, X, Ward, NC, Hodgson, JM. Nitrate causes a dose-dependent augmentation of nitric oxide status in healthy women. Food Funct. 2012;3(5):522–7.
23. Lundberg, JO, Weitzberg, E, Gladwin, MT. The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov. 2008;7(2):156–67.
24. Bui, AL, Horwich, TB, Fonarow, GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30–41.
25. Havranek, EP, Masoudi, FA, Westfall, KA, Wolfe, P, Ordin, DL, Krumholz, HM. Spectrum of heart failure in older patients: results from the National Heart Failure project. Am Heart J. 2002;143(3):412–7.
26. Kapil, V, Khambata, RS, Robertson, A, Caulfield, MJ, Ahluwalia, A. Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study. Hypertension. 2015;65(2):320–7.
27. Falis, R, Seman, M, Braat, S, Sortino, J, Allen, JD, Neil, CJ. Inorganic nitrate as a treatment for acute heart failure: a protocol for a single center, randomized, double-blind, placebo-controlled pilot and feasibility study. J Transl Med. 2017;15(1):172.
28. Palmer, RM, Ashton, DS, Moncada, S. Vascular endothelial cells synthesize nitric oxide from l-arginine. Nature. 1987;333(6174):664–6.
29. Ignarro, LJ, Buga, GM, Wood, KS, Byrns, RE, Chaudhuri, G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA. 1987;84(24):9265–9.
30. Palmer, RM, Ferring, AG, Moncada, S. Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327(6122):524–6.
31. Coggan, AR, Leibowitz, JL, Speear, CA, Kadkhodalay, A, Thomas, DP, Ramamurthy, S, Mahmood, K, Park, S, Waller, S, Farmer, M, et al. Acute dietary nitrate intake improves muscle contractile function in patients with heart failure: a double-blind, Placebo-controlled, randomized trial. Circ Heart Fail. 2015;8(5):914–20.
32. Zamani, P, Rawat, D, Shiva-Kumar, P, Geraci, S, Bhuvu, R, Konda, P, Doulias, PT, Ischiropoulos, H, Townsend, RR, Margules, KB, et al. Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation. 2015;131(4):371–80.